WaveBot: The Automated Trading Tool for This Bull Market

The 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But here’s the thing: most people won’t be able to keep up with the pace of the market. That’s why I want to tell you about WaveBot – an automated trading tool created by my good friends Joel and Adam.

Kenneth Hallock Biography and Net Worth

Director of Greenwich LifeSciences

Mr. Hallock has over 40 years of experience in general management and new venture start-ups. He is currently a senior manager and partner in a private start-up equipment manufacturing company and has been in these roles for over 10 years. Mr. Hallock has worked in large industrial corporations such as NL Industries, Inc. and Anderson, Clayton, and Co., which were subsequently acquired. Mr. Hallock received a BSE in Chemical Engineering from Princeton University, and an MBA from Harvard Business School.

How do I contact Kenneth Hallock?: The corporate mailing address for Mr. Hallock and other Greenwich LifeSciences executives is , , . Greenwich LifeSciences can also be reached via phone at 832-819-3232 and via email at [email protected]. Learn More on Kenneth Hallock's contact information.
Has Kenneth Hallock been buying or selling shares of Greenwich LifeSciences?: Kenneth Hallock has not been actively trading shares of Greenwich LifeSciences during the last quarter. Most recently, on Friday, January 21st, Kenneth Hallock bought 300 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $16.32 per share, with a total value of $4,896.00. Learn More on Kenneth Hallock's trading history.
Who are Greenwich LifeSciences' active insiders?: Greenwich LifeSciences' insider roster includes Frank Daugherty (Insider), Kenneth Hallock (Director), David McWilliams (Director), Snehal Patel (CEO), and Jaye Thompson (VP). Learn More on Greenwich LifeSciences' active insiders.
Are insiders buying or selling shares of Greenwich LifeSciences?: During the last year, Greenwich LifeSciences insiders bought shares 13 times. They purchased a total of 210,925 shares worth more than $3,001,129.50. The most recent insider tranaction occured on November, 21st when VP Jaye Thompson bought 1,000 shares worth more than $12,910.00. Insiders at Greenwich LifeSciences own 51.7% of the company. Learn More about insider trades at Greenwich LifeSciences.
Information on this page was last updated on 11/21/2024.

Kenneth Hallock Insider Trading History at Greenwich LifeSciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/21/2022	Buy	300	$16.32	$4,896.00

Kenneth Hallock Buying and Selling Activity at Greenwich LifeSciences

Greenwich LifeSciences Company Overview

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Today's Range

Now: $14.54

$14.28

$15.39

50 Day Range

MA: $13.79

$12.37

$15.29

2 Week Range

Now: $14.54

$8.00

$21.44

Volume

8,485 shs

Average Volume

39,467 shs

Market Capitalization

$191.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61